Table 2. Exome mutations, hTERT promoter mutations and G-allele status of anaplastic oligodendroglioma patients with short-term versus long-term survival treated with RT and PCV within NRG Oncology RTOG 9402.

	ST-1	ST-2	ST-3	ST-4	ST-5	ST-6	LT-1	LT-2	LT-3	LT-4	LT-5	LT-6	LT-7	Added patient 1	Added patient 2	Total number mutated
IDH1	-	M	-	M	M	M	M	M	M	M	M	M	-	M	-	11
CIC	-	M	M	-	M	-	M	-	M	M	M	M	-	-	-	8
FUBP1	-	-	-	-	M	-	-	M	M	M	M	-	M	M	M	8
NOTCH1	-	-	M	-	-	-	-	M	-	-	-	-	-	-	M	3
NIPBL	M	-	M	-	-	-	-	M	-	-	-	-	-	-	-	3
ESX1	-	-	M	-	-	-	-	-	-	-	M	M	-	-	-	2
PIK3CA	-	M	-	-	M	-	-	-	M	-	-	-	-	-	-	3
AC005014.2	-	-	M	-	-	M	-	-	-	-	-	-	-	-	-	2
EIF3L	-	-	M	M	-	-	-	-	-	-	-	-	-	-	-	2
FAM83A	-	-	M	-	-	-	-	-	-	M	-	-	-	-	-	2
RIF1	-	M	-	-	-	-	-	-	-	-	-	M	-	-	-	2
RLBP1L2	-	-	M	M	-	-	-	-	-	-	-	-	-	-	-	2
TTN	-	M	-	-	-	-	M	-	-	-	-	-	-	-	-	2
EIF4B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	M	1
EIF4E3	-	-	-	-	M	-	-	-	-	-	-	-	-	-	-	1
EPC2	-	-	-	-	M	-	-	-	-	-	-	-	-	-	-	1
KDM6B	-	-	-	-	M	-	-	-	-	-	-	-	-	-	-	1
ATRX	-	-	-	-	-	-	-	-	-	-	-	M	-	-	-	1
NOTCH2	-	-	-	M	-	-	-	-	-	-	-	-	-	-	-	1
NOTCH3	-	-	-	-	-	-	-	M	-	-	-	-	-	-	-	1
HOXD3	-	-	-	-	-	-	-	-	M	-	-	-	-	-	-	1
EEF1G	-	-	M	-	-	-	-	-	-	-	-	-	-	-	-	1
EIF3L	-	-	M	-	-	-	-	-	-	-	-	-	-	-	-	1
EPHA7	-	-	M	-	-	-	-	-	-	-	-	-	-	-	-	1
HDAC1	-	-	M	-	-	-	-	-	-	-	-	-	-	-	-	1
MGMT	-	-	M	-	-	-	-	-	-	-	-	-	-	-	-	1
MLL	-	-	M	-	-	-	-	-	-	-	-	-	-	-	-	1
MLL2	-	-	M	-	-	-	-	-	-	-	-	-	-	-	-	1
PIK3AP1	-	-	M	-	-	-	-	-	-	-	-	-	-	-	-	1
TP53	-	-	M	-	-	-	-	-	-	-	-	-	-	-	-	1
HDAC2	-	-	-	-	-	-	M	-	-	-	-	-	-	-	-	1
G-Allele	AA	AA	AA	AA	GA	AA	GA	AA	AA	GA	AA	AA	GA	GA	AA	N/A
hTERT	-	M	M	M	M	M	M	M	M	M	M	M	-	M	M
Survival (years)	0.5	0.5	4.2	4.9	5.5	6.4	8	11.2	11.3	12	13.3	16.2	16.8	9.5	14.6
PFS (years)	0.2	0.5	0.9	4.9	0.7	1.9	8	11.2	11.3	12	13.3	16.2	16.8	2.5	1.6
Progressive disease?	Yes	N/A*	Yes	N/A*	Yes	Yes	No	No	No	No	No	No	No	Yes	Yes

Survival data for the individual patients are shown. PFS = Progression free survival. *Death, unrelated to disease progression.